Sharma, Nitika

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P. (2019) · Journal of Oncology Pharmacy Practice

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 331

Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients

Greene, C. J., Attwood, K., Sharma, N. J., Gross, K. W., Smith, G. J., Xu, B., & Kauffman, E. C. (2017) · Oncotarget

Renal cell carcinoma treatmentFerroptosis and cancer prognosis

Cited by 87